RxDoctor Payments Data

Sophia Sandhu, MD

Dermatology · Torrance, CANPI 1912311655

Payments from drug & device makers

$4,275in general payments, 2019–2025

Across 186 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$709
  • Johnson & Johnson$622
  • Novartis$327
  • Sanofi$261
  • Dermavant Sciences, Inc.$253
  • Sun Pharmaceutical Industries Inc.$242
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,275100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,275 in reported general payments places this provider in the 65th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$96,693
Medicare patients
380
Services billed
1,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyriziRisankizumab-Rzaa11$244,181
OtezlaApremilast22$104,819
Humira(Cf) PenAdalimumab13$88,550
Dupixent PenDupilumab15$55,996
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc188$9,043
Tacrolimus46$6,890
Ketoconazole367$6,533
Fluocinonide76$4,384
Calcipotriene14$2,441
Clobetasol Propionate27$2,313
Betamethasone Dipropionate25$2,022
Hydrocortisone123$2,020
Triamcinolone Acetonide138$1,643
Mometasone Furoate66$1,615
Metronidazole32$1,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSkyrizi$709$244,18111 claims
AmgenOtezla$217$104,81922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,875 dermatology providers in California.

Other dermatology in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →